Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905762 · ClinicalTrials.gov registry record · Phase 1
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT00905762 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 119 participants.
The verdict
NCT00905762, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days.
Interventions
- DRUG Moxifloxacin
- DRUG Gatifloxacin
- DRUG Besifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00905762
The ClinicalTrials.gov registry entry for NCT00905762 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT00905762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00905762 about?
NCT00905762 is a clinical study titled "Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation". The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by t...
What is the current status of trial NCT00905762?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2009-03. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00905762?
The interventions under investigation include: Moxifloxacin (DRUG), Gatifloxacin (DRUG), Besifloxacin (DRUG).
Who is sponsoring clinical trial NCT00905762?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.